ELV

The headline compares ELV and RVTY to determine which is a better value. It suggests a value analysis between the two stocks.

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will

TD Cowen analyst Ryan Langston keeps a Buy rating on Elevance Health and lifts the price target from $465 to $495. This indicates a positive outlook for the stock.

Elevance Health's Q3 2026 results show earnings per share of $6.30 and net income of $1.37 billion on over $51 billion of revenue. The stock rose 2.6% to about $445, reflecting investor optimism despite a lower EPS than the prior quarter.

The article asks what factors will influence UnitedHealth Group stock in the next six months.

UBS analyst A.J. Rice maintains a Buy rating on Elevance Health and raises the price target from $460 to $523. This signals a bullish view from UBS.

Guggenheim analyst Jason Cassorla keeps a Buy rating on Elevance Health and lifts the price target from $460 to $485. The firm sees upside potential for the stock.

Morgan Stanley analyst Erin Wright keeps an Equal-Weight rating on Elevance Health and raises the price target from $404 to $449. This suggests a moderate positive outlook.